Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Embolization of post-partial nephrectomy upper calyceal-perirenal urinary fistula using onyx-34: A novel application of a (pseudo-) liquid embolic agent.

Indian journal of urology : IJU : journal of the Urological Society of India·2026
Same author

Toward a PSMA PET-mpMRI pathway for biopsy decision-making in men with suspected prostate cancer: interim results from the prospective BIOPSTAGE trial.

Frontiers in oncology·2026
Same author

Correction: Prostatic artery embolization with glue for benign prostatic hyperplasia in elderly patients: three-year results.

La Radiologia medica·2025
Same author

Prostatic artery embolization with glue for benign prostatic hyperplasia in elderly patients: three-year results.

La Radiologia medica·2025
Same author

Accuracy of automated computer-aided risk scoring systems to estimate the risk of COVID-19: a retrospective cohort study.

BMC research notes·2024
Same author

Antibiotic prophylaxis in invasive urodynamics, a Delphi consensus of the Italian Society of Urodynamics (SIUD).

Neurourology and urodynamics·2024
Same journal

Nanotechnology-Stem Cell Strategies in 3D Glioblastoma Organoid: Targeting Glioma Stem Cells Within a Complex Tumor Microenvironment.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Mapping the 3D Chromosome Organization of a Biosynthetic Gene Cluster by Capture Hi-C (CHi-C).

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Mapping the 3D Chromosome Organization of Streptomyces by Hi-C.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

CUT&Tag Epigenomic Profiling of Biosynthetic Gene Clusters in Arabidopsis thaliana.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Rhizobium rhizogenes-Mediated Hairy Root Transformation Protocol for Lotus japonicus and Other Legumes.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Characterization of Bioactive Saponins from Sea Cucumbers.

Methods in molecular biology (Clifton, N.J.)·2026
See all related articles

Related Experiment Video

Updated: Nov 15, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.5K

PCA3 in Prostate Cancer.

Roberta Gunelli1, Eugenia Fragalà1, Massimo Fiori2

  • 1Department of Urology, GB Morgagni Hospital, Forlì, Italy.

Methods in Molecular Biology (Clifton, N.J.)
|March 2, 2021
PubMed
Summary
This summary is machine-generated.

The Prostate cancer antigen 3 (PCA3) urine test is a sensitive and specific biomarker for prostate cancer. Combining PCA3 with PSA may help identify men needing repeat biopsies after negative results.

Keywords:
BiomarkerDD3PCA3Prostate BiopsyProstate Cancer

More Related Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

949
Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts
09:43

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts

Published on: August 1, 2025

444

Related Experiment Videos

Last Updated: Nov 15, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.5K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

949
Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts
09:43

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts

Published on: August 1, 2025

444

Area of Science:

  • Urology
  • Oncology
  • Biomarker Discovery

Background:

  • Prostate cancer antigen 3 (PCA3) is an established urinary biomarker for prostate cancer.
  • Current diagnostic pathways often involve repeat biopsies, leading to patient burden and healthcare costs.

Purpose of the Study:

  • To evaluate the utility of the PCA3 assay as a minimally invasive tool in prostate cancer diagnosis.
  • To explore the combined use of PCA3 and Prostate-Specific Antigen (PSA) for guiding rebiopsy decisions.

Main Methods:

  • Analysis of PCA3 levels in urine samples.
  • Correlation of PCA3 assay results with prostate cancer diagnosis and biopsy outcomes.
  • Assessment of PCA3 in conjunction with PSA values.

Main Results:

  • The PCA3 assay demonstrates high specificity and sensitivity for prostate cancer detection.
  • PCA3 shows promise in identifying men with prior negative biopsies who may benefit from rebiopsy.
  • Combined biomarker strategies are emerging for improved cancer evaluation.

Conclusions:

  • The PCA3 assay is a valuable, minimally invasive biomarker for prostate cancer.
  • Combining PCA3 with PSA can enhance the decision-making process for repeat prostate biopsies.
  • Future trends indicate a move towards multi-biomarker panels for accurate cancer assessment and reduced unnecessary procedures.